--- title: "Effect of Paragraph IV and generics on brand pharma. | Sutter Health" description: "Paragraph IV decisions disproportionately involve the highest revenue drugs, significant patent protection, and a portion of brand drugs facing generic entry." url: "https://www.sutterhealth.org/research/publications/effect-paragraph-iv-generics-brand-pharma-1055312883" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Effect of Paragraph IV and generics on brand pharma. # The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Panattoni LE. _J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8._ 2011-01-01 ## Abstract This purpose of this paper is to investigate the impact of Paragraph IV patent infringement decisions on brand drug pharmaceutical firms. Paragraph IV decisions determine whether a generic firm can enter before the period of exclusivity ends. I construct a novel dataset of all Paragraph IV decisions and find that they disproportionately involve the highest revenue drugs, significant periods of patent protection, and a non-trivial portion of all brand drugs facing generic entry. I also estimate the impact of Paragraph IV decisions on brand firm profitability and find they have large value consequences. [PubMed abstract](http://www.ncbi.nlm.nih.gov/pubmed/21074873) ## Research topics - [Health Policy](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Health+Policy%5C%22%22) - [Health Services](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Health+Services%5C%22%22) - [Medical Informatics](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Medical+Informatics%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [A clinician's guide to privacy and communication in the ICU.](https://www.sutterhealth.org/research/publications/clinician-privacy-communication-icu-1055312509) Francis L, Vorwaller MA, Aboumatar H, Frosch DL, Halamka J, Rozenblum R, Rubin E, Lee BS, Sugarman J, Turner K, Brown SM; Privacy, Access, and Engagement Task Force of the Libretto Consortium of the Gordon and Betty Moore Foundation. Crit Care Med. \[Epub ahead of print\] 2016 Dec 02 - Publication ### [Electronic health record logs indicate that physicians split time evenly between seeing patients and desktop medicine.](https://www.sutterhealth.org/research/publications/mds-split-time-evenly-see-pts-desktop-med-1055312310) Tai-Seale M, Olson CW, Li J, Chan AS, Morikawa C, Durbin M, Wang W, Luft HS. Health Aff. 36:655-662; doi:10.1377/hlthaff.2016.0811. 2017 Apr 01 - Publication ### [When does adoption of health information technology by physician practices lead to use by physicians within the practice?](https://www.sutterhealth.org/research/publications/adoption-and-use-of-health-it-by-physicians-1055312889) McClellan SR, Casalino LP, Shortell SM, Rittenhouse DR. J Am Med Inform Assoc. 20(e1):e26-32. doi: 10.1136/amiajnl-2012-001271. Epub 2013 Feb 8. 2013 Jun 01 - Publication ### [Patient experiences in selecting a Medicare Part D prescription drug plan.](https://www.sutterhealth.org/research/publications/pt-experiences-selecting-medicare-part-d-rx-drug-plan-1055312300) Stults CD, Baskin AS, Bundorf MK, Tai-Seale M. J Patient Experience. https://doi.org/10.1177/2374373517739413 2017 Nov 21 - Publication ### [Medicare annual preventive care visits: use increased among fee-for-service patients, but many do not participate.](https://www.sutterhealth.org/research/publications/medicare-preventive-care-in-fee-for-svce-pts-1055312874) Chung S, Lesser LI, Lauderdale DS, Johns NE, Palaniappan LP, Luft HS. Health Aff (Millwood). 34(1):11-20. doi: 10.1377/hlthaff.2014.0483. 2015 Jan 01 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/effect-paragraph-iv-generics-brand-pharma-1055312883#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Effect of Paragraph IV and generics on brand pharma."}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/effect-paragraph-iv-generics-brand-pharma-1055312883#medicalscholarlyarticle","name":"The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.","headline":"Effect of Paragraph IV and generics on brand pharma.","abstract":"This purpose of this paper is to investigate the impact of Paragraph IV patent infringement decisions on brand drug pharmaceutical firms. Paragraph IV decisions determine whether a generic firm can enter before the period of exclusivity ends. I construct a novel dataset of all Paragraph IV decisions and find that they disproportionately involve the highest revenue drugs, significant periods of patent protection, and a non-trivial portion of all brand drugs facing generic entry. I also estimate the impact of Paragraph IV decisions on brand firm profitability and find they have large value consequences.","description":"Paragraph IV decisions disproportionately involve the highest revenue drugs, significant patent protection, and a portion of brand drugs facing generic entry.","keywords":["Health Policy","Health Services","Medical Informatics"],"datePublished":"2011-01-01","url":"https://www.sutterhealth.org/research/publications/effect-paragraph-iv-generics-brand-pharma-1055312883","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"21074873"},{"@type":"PropertyValue","propertyID":"DOI","value":"10.1016/j.jhealeco.2010.09.004"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/21074873/","https://doi.org/10.1016/j.jhealeco.2010.09.004"],"isPartOf":{"@type":"Periodical","name":"J Health Econ"},"author":[{"@type":"Person","name":"Panattoni LE"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Health Policy","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Health+Policy%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Health Services","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Health+Services%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Medical Informatics","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Medical+Informatics%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/effect-paragraph-iv-generics-brand-pharma-1055312883","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/effect-paragraph-iv-generics-brand-pharma-1055312883#breadcrumblist"}}} ```